Sattlecker, M; Khondoker, M; Proitsi, P; Williams, S; Soininen, H; Kłoszewska, I; Mecocci, P; ... Dobson, RJ; + view all Sattlecker, M; Khondoker, M; Proitsi, P; Williams, S; Soininen, H; Kłoszewska, I; Mecocci, P; Tsolaki, M; Vellas, B; Lovestone, S; Dobson, RJ; - view fewer (2015) Longitudinal Protein Changes in Blood Plasma Associated with the Rate of Cognitive Decline in Alzheimer's Disease. Journal of Alzheimer's Disease , 49 (4) pp. 1105-1114. 10.3233/JAD-140669.

Preview	Text Manuscript.revised.final_Martina-etal-2015_JAD.pdf Download (637kB) | Preview
Preview	Text Supplementary.material.pdf Download (445kB) | Preview

Abstract

Biomarkers of Alzheimer's disease (AD) progression are needed to support the development of urgently needed disease modifying drugs. We employed a SOMAscan assay for quantifying 1,001 proteins in blood samples from 90 AD subjects, 37 stable mild cognitive impaired (MCI) subjects, 39 MCI subjects converting to AD within a year and 69 controls at baseline and one year follow up. We used linear mixed effects models to identify proteins changing significantly over one year with the rate of cognitive decline, which was quantified as the reduction in Mini Mental State Examination (MMSE) scores. Additionally, we investigated proteins changing differently across disease groups and during the conversion from MCI to AD. We found that levels of proteins belonging to the complement cascade increase significantly in fast declining AD patients. Longitudinal changes in the complement cascade might be a surrogate biomarker for disease progression. We also found that members of the cytokine-cytokine receptor interaction pathway change during AD when compared to healthy aging subjects.

Download activity - last month

Export as XMLJSONCSV

Download activity - last 12 months

Export as CSVJSONXML

Downloads by country - last 12 months

Export as CSVXMLJSON

Archive Staff Only

View Item